Form 4: Akari Therapeutics Director Gaslightwala Reports Acquisition and Disposal of Shares and Warrants
SEC Form 4 Filing
Director Abizer Gaslightwala reports acquiring and disposing of Akari Therapeutics shares and warrants in a private placement.
Summary
- On March 6, 2025, Abizer Gaslightwala, a director of Akari Therapeutics Plc, reported transactions involving the company's securities.
- Gaslightwala acquired 133,928 American Depositary Shares (ADS) and accompanying Series A and Series B warrants in a private placement.
- The purchase price was $1.12 per ADS and accompanying warrants.
- Each ADS represents 2,000 ordinary shares of Akari Therapeutics.
- Gaslightwala also disposed of 181,428 ADS.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The acquisition and disposal of shares by a director may influence investor perception of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| February 27, 2025 | Date of the Securities Purchase Agreement. |
| March 6, 2025 | Date of the reported transactions: acquisition and disposal of shares and warrants. |
| March 6, 2026 | Expiration date of Series A Warrants. |
| March 6, 2030 | Expiration date of Series B Warrants. |
| March 10, 2025 | Date of signature of the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.